Publications by authors named "F Jackson-Spence"
Article Synopsis
- The study looked at how different treatments affect kidney tumors in patients with advanced kidney cancer.
- It found that a combination of immune therapy and a specific type of cancer drug worked best, reducing tumor size significantly in 50% of patients.
- The researchers suggest testing this treatment more to see if it can help more patients before surgery for kidney cancer.
The landscape of the management of renal cell carcinoma has evolved substantially in the last decade, leading to improved survival in localised and advanced disease. We review the epidemiology, pathology, and diagnosis of renal cell carcinoma and discuss the evidence for current management strategies from localised to metastatic disease. Developments in adjuvant therapies are discussed, including use of pembrolizumab-the first therapy to achieve overall survival benefit in the adjuvant setting.
View Article and Find Full Text PDFArticle Synopsis
- Taxane-based chemotherapy, specifically paclitaxel, is commonly used for treating platinum- and immunotherapy refractory metastatic urothelial carcinoma (mUC), but survival outcomes are generally poor and biomarkers for predicting outcomes are lacking.
- A study was conducted using whole-transcriptome profiles from patients enrolled in a trial (PLUTO) to evaluate gene signatures related to survival, focusing on factors like immuno-oncology, angiogenesis, and genome instability.
- Results indicated that patients with high expressions of genome instability and evading growth suppressors experienced significantly better progression-free survival (PFS) and overall survival (OS), while activation of angiogenesis was associated with worse outcomes across both treatment cohorts.
Antibody-drug conjugates have transformed treatment for urothelial cancer (UC). Enfortumab vedotin is the new standard of care in the first-line setting for advanced UC. A personalised approach targeting HER2 in UC is currently being explored.
View Article and Find Full Text PDFUpper tract urothelial carcinoma (UTUC) is an aggressive and difficult malignancy to treat. Owing to its rarity and the lack of specific high-level data, management mirrors that of urothelial cancer of the bladder (UCB). Over the past decade, UTUC has shown minimal improvement in survival rates.
View Article and Find Full Text PDF